Clinical Trial Search

Primary: Change From Screening Period Baseline to Maintenance Period in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score. — -4.60; -1.44…

Primary: Change From Baseline in Mean Unified Huntington's Disease (HD) Rating Scale Total Maximal Chorea (UHDRS TMC) Score — -2.4 score on a scale — p=0.27

Primary: Change in Total Maximal Chorea (TMC) Score of the UHDRS® for Subjects Not Taking Neuroleptics During the Trial (mITT - N=122) — -2.19; -2.42; -3.46 units on a scale…

Primary: Number of Patients With at Least One Adverse Event — 119 Participants

Primary: Change From Baseline (Average of Screening and Day 0) in the Average TMC Scores From Weeks 9 & 12 — -4.42; -1.93 Units on a scale — p=<0.0001

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During Entire…

Primary: Tinetti Mobility Test Score — 19.91; 17.09 Total Tinetti Mobility Test Score (TMT)

Primary: Change From Baseline in the Total Motor Score (TMS) Assessment of the Unified Huntington Disease Rating Scale (UHDRS) After 26 Weeks of Treatment. — 0.4; -0.8; -1.4…

Primary: Safety and Tolerability of PBT2 in Patients With HD — 32; 30; 28 participants

Primary: Gait Parameters — 1.289; 1.292 meters per second

Primary: Change in Stroop Interference Score — -1.97; -1 score on a scale

Primary: Quantitative Electroencephalography Absolute Delta Power. — 43.45; 10.11 microvolts squared — p=<0.0000001

Primary: Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the UHDRS Motor Assessments) at Week 12 — -1.40; -1.30; -2.49; -2.32 units on…

Primary: Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the Unified Huntington's Disease Rating Scale [UHDRS] Motor Assessments) at…

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 46; 43; 49 Participants

Primary: Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug — 2; 1; 3; 3 Participants

Primary: Change From Baseline in the Composite Unified Huntington's Disease Rating Scale (cUHDRS) Score-Z Score — 0.103; -0.367; -0.139; -1.173 Scores on a Scale

Primary: Irritability as Assessed by The Irritability Scale. — 27.5 score on a scale

Primary: Change in the Hopkins Verbal Learning Test - Revised for Delayed Recall (HVLT-R-delayed Recall)

Primary: Change From Baseline in the Movement Disorder-Childhood Rating Scale (MD-CRS) Part II Total Score (Movement Disorder Severity, Centrally Read) at Week 15 — -0.4; -1.5…

Primary: Change From Baseline in the Following Clinical Endpoints at 3, 9, and 15 Months: cUHDRS, TFC, TMS, SDMT, SWR Test and IS — 0.19; -0.12; -0.76; -0.24 Scores on a scale

Primary: Difference in Huntington's Disease Cognitive Assessment Battery (HD-CAB) Composite Score Between Participants With HD vs HP at Baseline — -3.3657; 0.0000 Z score…

Primary: Conners' Adult Attention Rating Scale (CAARS) — -2.88; -2.24 units on a scale — p=0.63

Primary: Change From Baseline in UHDRS-TMS at Week 52 — 1.3; 1.4; 2.0; 11.0 units on a scale — p=0.4853

Primary: Number of Participants With Treatment-related Adverse Events (TEAEs) — 12; 3; 6; 6 Participants

Primary: Tolerability of SRX246 — 25; 27; 30 Participants

Primary: Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26 — -4.79; -3.37; -3.09; -4.13 score on a scale — p=0.3202

Primary: Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT) — -1.18; -0.95 score on a scale — p=0.1670

Primary: Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM) — -1.4; -2.1; -3.2; -3.3…

Primary: Change From Baseline in the SDMT — 2.0; 0.8 score on a scale — p=0.1675